Selection of retapamulin, a novel pleuromutilin for topical use.
The in vitro activity of retapamulin was determined and compared to that of topical and community antibiotics. The MIC(90)s of retapamulin against Staphylococcus aureus and Streptococcus pyogenes were 0.12 microg/ml and 0.016 microg/ml, respectively. Retapamulin has a low propensity to select resistance and produces an in vitro postantibiotic effect.
Rittenhouse
Stephen
S
Department of Microbiology Research, MMPD CEDD, GlaxoSmithKline Pharmaceuticals, 1250 S. Collegeville Rd, Collegeville, PA 19426-0989, USA. Stephen_Rittenhouse@GSK.com
Biswas
Sanjoy
S
Broskey
John
J
McCloskey
Lynn
L
Moore
Terrance
T
Vasey
Sandra
S
West
Joshua
J
Zalacain
Magdalena
M
Zonis
Rimma
R
Payne
David
D
D000891:Anti-Infective Agents, Local / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D004224:Diterpenes / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D016712:Mupirocin / Q000494:pharmacology; D011083:Polycyclic Compounds; D017192:Skin Diseases, Bacterial / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D000097567:Pleuromutilins
D000891:Anti-Infective Agents, Local; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004224:Diterpenes; D016712:Mupirocin; D011083:Polycyclic Compounds; D000097567:Pleuromutilins; C508887:retapamulin